Targeting cancer metabolism: Why Bayer and Pfizer are restructuring - and why Vidac Pharma is filling a scientific gap

Pfizer and Bayer: The need to reinvent

The current situation is serious for the established market leaders. Pfizer, the US giant, has to manage the period following its enormous Covid revenue and is desperately searching for new blockbusters in oncology. Its strategy is focused on acquisitions and realigning its pipeline to navigate the looming patent cliffs. The situation at Bayer is similarly complex. The Leverkusen-based company is in the midst of a historic transformation, with investors closely watching to see whether the strategic realignment of its pharmaceuticals division will bear fruit.

Both companies are under pressure to increase their research efficiency. The era of simple chemical blockbusters is over: the future belongs to complex biological mechanisms that tackle diseases at their root. However, innovation is difficult to enforce in corporate structures, which is why smart money investors are increasingly turning their attention to specialized niche players who deliver precisely these scientific breakthroughs.

Vidac Pharma: The revolution in cancer metabolism

This is where Vidac Pharma enters the stage. The Company pursues an approach that is radically different from conventional chemotherapy or immunotherapy. Vidac targets the Warburg effect, a well-known anomaly in tumor metabolism that enables rapid growth and immune evasion. By developing molecules that detach the enzyme hexokinase 2 (HK2) from the mitochondria, Vidac effectively deprives the tumor of its fuel. This mechanism has the potential not only to prevent the tumor from growing, but also to make it vulnerable to the body's own immune system again.

The validation of this technology is progressing at an impressive pace. As the Company recently announced, the broad US patent for HK2 modulators has been granted, securing the world's most important pharmaceutical market for Vidac. In addition, Vidac Pharma has launched the "TME++" research consortium for pediatric brain tumors, a step that underscores the clinical relevance and confidence of the scientific community. The progress made in clinical trials demonstrates that the technology works. The Company is actively preparing for the next phase as a clinical entity, which is often the trigger for a revaluation in the biotech industry.

The analysts' verdict: A sleeping giant?

The capital market does not yet appear to have fully grasped the potential of this platform technology, which represents an opportunity for countercyclical investors. In their latest update in November, analysts at Sphene Capital issued a clear "Buy" recommendation and set a price target of EUR 4.20 for Vidac Pharma. Compared to the current trading level, this implies massive upside potential. Publicly available trading data also confirms the growing interest in the stock, which is tradable on several German stock exchanges.

While Bayer and Pfizer have to move billions to achieve single-digit percentage growth, Vidac Pharma offers classic biotech leverage. The Company combines a scientifically validated platform with strong patent protection and a clear clinical roadmap. At a time when large pharmaceutical companies are desperately searching for new mechanisms of action to fill their pipelines, Vidac is not only an investment case in its own right, but also a logical takeover candidate. Anyone who believes that targeting cancer metabolism will be the next big trend in oncology cannot ignore Vidac Pharma. This is all the more true given the still manageable market capitalization of around EUR 42 million. After the stock recently gained ground again, further investors could take notice of Vidac shares in view of the interesting equity story, coupled with the current valuation level. The stock is an exciting biotech candidate and belongs on every watch list.